About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 111 record(s)
Req # A-2021-000599
Documents in the custody of Health Canada regarding the health or religious exemption of kratom from the Controlled Drugs and Substances Act, including, but not limited to, memoranda, position papers, internal opinions, research constituting the basis for decision-making regarding kratom and/or pertaining to the health or religious exemption of kratom. Timeline: July 1 2018 to July 15 2021.Organization: Health Canada
July 2021
Req # A-2018-001904
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 18-075681-361.Organization: Health Canada
July 2021
Req # A-2019-001157
Adverse Reaction Reports (AERs). Report numbers: E2B_00994539, E2B_00994574, E2B_00994399, E2B_00994578, E2B_00994585, E2B_00414407, E2B_00612733, E2B_00999629, E2B_01000771, E2B_00956962, 000668277.Organization: Health Canada
July 2021
Req # A-2019-001422
Adverse Reaction Reports (AERs). Report numbers: E2B_02446830, 000719995, E2B_02331315, E2B_02355523, E2B_02582494, E2B_02147870, 000726432, E2B_02057660, E2B_01843452, E2B_01564258, E2B_01882540, 000706720, E2B_01877973, E2B_01860249, E2B_01853586, E2B_01853589, E2B_01813303, E2B_01955420, E2B_02231550, E2B_02461661.Organization: Health Canada
July 2021
Req # A-2019-001470
Adverse Reaction Reports (AERs) for C1 Esterase, IVIG, and Icatibant. Report numbers: E2B_02670025, E2B_02706731, E2B_02660972, E2B_02703838.Organization: Health Canada
July 2021
Req # A-2019-001641
Adverse Reaction Reports (AERs) for FUROSEMIDE. Report numbers: E2B_02464932, E2B_02470138, E2B_02476388, E2B_02481818, 722693, E2B_02059576, E2B_02012213, E2B_02503071, E2B_02038328, E2B_02537617, E2B_02540245, E2B_02549913, E2B_02591638, E2B_02600471, E2B_02619083.Organization: Health Canada
July 2021
Req # A-2019-001694
Adverse Reaction Reports (AERs). Report numbers: E2B_02763534, E2B_02764556, E2B_02764781, E2B_02764830.Organization: Health Canada
July 2021
Req # A-2019-001842
Adverse Drug Reaction (ADR). Report number: E2B_02805583.Organization: Health Canada
July 2021
Req # A-2019-001847
Adverse Drug Reaction (ADR). Report Number: E2B_02798893.Organization: Health Canada
July 2021
Req # A-2019-001903
Adverse Reaction Reports (AERs) for LEFLUNOMIDE. Report numbers: E2B_02405089, E2B_02406154, E2B_02121517, E2B_02235999, E2B_01961838, 725412 ,E2B_02483757, E2B_00698676, E2B_02441376, E2B_02485493, E2B_02392067, E2B_02486374, E2B_02487190, E2B_02487535, E2B_02463616, E2B_02489775, E2B_02467537, E2B_02475476, E2B_02477065, E2B_02477794.Organization: Health Canada
July 2021